Organization
Thomas Jefferson University, Philadelphia, PA
3 abstracts
Abstract
Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results.Org: Division of Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Tennessee Oncology, PLLC, Sarah Cannon Research Institute, Nashville, TN, Sarah Cannon Research Institute at HealthONE, Denver, CO, NEXT Oncology Virginia, Fairfax, VA,
Abstract
Comparison of incident breast cancer cases in the largest national US tumor registries.Org: Department of Surgery, Duke University Medical Center, Durham, NC, Department of Biostatistics and Bioinformatics, Duke Cancer Institute, Duke University Medical Center, Durham, NC, Duke University Medical Center, Durham, NC, Thomas Jefferson University, Philadelphia, PA, Yale University, New Haven, CT,
Abstract
The changing landscape of small-cell lung cancer.Org: Division of Oncology, Washington University in St. Louis School of Medicine, Saint Louis, MO, Washington University School of Medicine, St. Louis, MO, Thomas Jefferson University, Philadelphia, PA, Washington University School of Medicine in St. Louis, St. Louis, MO, Duke Cancer Institute, Duke University School of Medicine, Durham, NC,